FUS inactivation promotes leptomeningeal metastasis of lung cancer through the up-regulation of CD36

The prognosis of non–small cell lung cancer (NSCLC) with leptomeningeal metastasis (LM) is dismal. The regulators of LM progression remain elusive, thus impeding effective clinical intervention. Here, we performed in vivo genome-wide CRISPR-based screens and found that fused in sarcoma (FUS) ablation promoted LM in both PC9 and A549 cells. FUS repressed CD36 expression by directly interacting with and destabilizing PPARA ( peroxisome proliferator–activated receptor α) messenger RNA. CD36 augmented fatty acid uptake and oxidative phosphorylation in NSCLC cells. Matrix metallopeptidase 2 (MMP2) was up-regulated through CD36-mediated fatty acid metabolism, which enabled NSCLC cells to disrupt the endothelial barrier. FUS-deficient NSCLC cells increased the expression of neuroendocrine differentiation (NED)–related markers, including SRY-box transcription factor 2 (SOX2), microtubule-associated protein 2 (MAP2), enolase 2 (NSE), and synaptophysin (SYP). They also exhibited neurite-like extensions and expanded in cerebrospinal fluid–supplemented medium in a CD36-dependent manner. Mechanistically, fatty acid uptake increased acetyl-coenzyme A and H3K27ac modifications to promote the expression of NED signature genes and MMP2 in NSCLC cells. Genetic or pharmacological inhibition of CD36 or inhibition of NED-related markers in NSCLC cells hindered LM and prolonged survival in mice. In patients with NSCLC, down-regulation of FUS or up-regulation of CD36 or SYP was associated with progression to LM. Thus, CD36-mediated fatty acid metabolism and NED signature are crucial for progression to LM in NSCLC, highlighting CD36 as a promising therapeutic target to limit the progression of LM.

Authors

Institutions

Publication Details

Journal
Science Translational Medicine
Published
2026-08-26
DOI
https://doi.org/10.1126/scitranslmed.aee1083
Primary Topic
Cancer, Lipids, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

FUS inactivation promotes leptomeningeal metastasis of lung cancer through the up-regulation of CD36

Shouheng Lin, Yang-Si Li, Xiwei Wang, Kai Yin et al.
Science Translational Medicine
Cancer, Lipids, and Metabolism
article

FUS inactivation promotes leptomeningeal metastasis of lung cancer through the up-regulation of CD36

Shouheng Lin, Yang-Si Li, Xiwei Wang, Kai Yin, Fa-Man Xiao, Jean Paul Thiery, Ziyuan Duan, Georgia Carson, Hai‐Yan Tu, Youguo Long, Qiting Wu, Yao Yao, Xu‐Chao Zhang, Mei-Mei Zheng, Xichen Bao, Qing Zhou, Duo Li, Zhihong Chen, Peng Li, Si‐Yang Maggie Liu, Yi-Long Lung Cancer Wu, Li‐Xu Yan, Wanjun Li, Ben‐Yuan Jiang, Diwei Zheng, Lu Zeng, Jin-Ji Yang, Wen-Zhao Zhong, Bin-Chao Wang, Zhiping Wu, Hua-Jun Chen
article en

Abstract

The prognosis of non–small cell lung cancer (NSCLC) with leptomeningeal metastasis (LM) is dismal. The regulators of LM progression remain elusive, thus impeding effective clinical intervention. Here, we performed in vivo genome-wide CRISPR-based screens and found that fused in sarcoma (FUS) ablation promoted LM in both PC9 and A549 cells. FUS repressed CD36 expression by directly interacting with and destabilizing PPARA ( peroxisome proliferator–activated receptor α) messenger RNA. CD36 augmented fatty acid uptake and oxidative phosphorylation in NSCLC cells. Matrix metallopeptidase 2 (MMP2) was up-regulated through CD36-mediated fatty acid metabolism, which enabled NSCLC cells to disrupt the endothelial barrier. FUS-deficient NSCLC cells increased the expression of neuroendocrine differentiation (NED)–related markers, including SRY-box transcription factor 2 (SOX2), microtubule-associated protein 2 (MAP2), enolase 2 (NSE), and synaptophysin (SYP). They also exhibited neurite-like extensions and expanded in cerebrospinal fluid–supplemented medium in a CD36-dependent manner. Mechanistically, fatty acid uptake increased acetyl-coenzyme A and H3K27ac modifications to promote the expression of NED signature genes and MMP2 in NSCLC cells. Genetic or pharmacological inhibition of CD36 or inhibition of NED-related markers in NSCLC cells hindered LM and prolonged survival in mice. In patients with NSCLC, down-regulation of FUS or up-regulation of CD36 or SYP was associated with progression to LM. Thus, CD36-mediated fatty acid metabolism and NED signature are crucial for progression to LM in NSCLC, highlighting CD36 as a promising therapeutic target to limit the progression of LM.

Science Translational MedicineVol. 18(864)
Department of Health (CN), Jinan University (CN), Chinese University of Hong Kong (HK), Guangzhou Institutes of Biomedicine and Health (CN), Biotronik (Singapore) (SG), Guangdong Academy of Medical Sciences (CN), First Affiliated Hospital of Jinan University (CN), University of Hong Kong (HK)
National Key Research and Development Program of China
Good health and well-being
Openalex Percentile: Top 14%
Cancer, Lipids, and Metabolism
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.